Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Matinas BioPharma Holdings, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
MTNB
NYSE American
2830
www.matinasbiopharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Matinas BioPharma Holdings, Inc.
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
- Feb 7th, 2025 12:30 pm
Matinas BioPharma Receives NYSE Noncompliance Notice
- Jan 10th, 2025 10:15 pm
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
- Oct 31st, 2024 10:30 am
Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested
- Sep 2nd, 2024 1:21 pm
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
- Aug 14th, 2024 8:05 pm
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
- Aug 7th, 2024 11:00 am
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
- Jun 24th, 2024 12:30 pm
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
- Jun 13th, 2024 11:00 am
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
- May 16th, 2024 11:00 am
Q1 2024 Matinas BioPharma Holdings Inc Earnings Call
- May 10th, 2024 5:22 pm
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call Transcript
- May 10th, 2024 4:46 pm
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
- May 9th, 2024 8:05 pm
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
- May 7th, 2024 12:00 pm
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
- May 2nd, 2024 11:00 am
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
- Apr 30th, 2024 12:00 pm
Matinas BioPharma Prices $10 Million Registered Direct Offering
- Apr 3rd, 2024 12:30 pm
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript
- Apr 1st, 2024 6:24 pm
Q4 2023 Matinas BioPharma Holdings Inc Earnings Call
- Mar 28th, 2024 10:46 am
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
- Mar 27th, 2024 8:05 pm
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
- Mar 25th, 2024 12:00 pm
Scroll